EN

NEUROASPIS

NEUROASPIS® plp10

A NOVEL & PIONEER INTERVENTION FOR MULTIPLE SCLEROSIS

NEUROASPIS® plp10 is probably the first patented combination and specially formulated dietary supplement in Europe used for medical purposes in order to support the treatment of MS patients in particular and other related neurodegenerative diseases.

Through a diligent examination of the disease’s modus operandi through a systems medicine approach, the ingredients and their relative concentrations were chosen so the cocktail provides the evident neuro-protective benefits.

NEUROASPIS® plp10 is a produce of more than 10 years of research and clinical development, where the Clinical Study Phase II is finished and published in 2013 in BMJ, while the Clinical Trial of Phase III with 220 patients is under way.

NEUROASPIS® plp10 embodies significant experience and know-how in Multiple Sclerosis. The proof of concept Phase II clinical trial was conducted under a stringent protocol with 80 patients. The clinical trial was conducted for a total period of 42 months, of which the 12 final months were post-intervention. The 12 months post-intervention highlight the positive effects of the formulation even in subsequent periods, and in fact pin-point these positive effects to the ingredients used, as the period coincides with their flush-out period.

Manufacturer & commercial rights holder: Aniva International S.A.

For more information please visit www.neuroaspis.com